CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.77B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.78: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.46BCHF1.77B · vs all stocks (USD)
Trailing P/E
105.00xRevenue (TTM)
433.43MEUR526.21M · vs all stocks (USD)
Profit Margin
3.15%Beta
1.00xvs all stocks
52-Week Change
81.69%vs all stocks
Market Capitalization
1.46BCHF1.77B · vs all stocks (USD)
Enterprise Value
1.46BCHF1.77B · vs all stocks (USD)
Trailing P/E
105.00xForward P/E
30.24xPrice to Sales (TTM)
3.17xPrice to Book (MRQ)
4.38xEnterprise to Revenue
3.36xEnterprise to EBITDA
20.45xProfit Margin
3.15%Operating Margin
9.29%Return on Assets (TTM)
3.38%Return on Equity (TTM)
4.24%Revenue (TTM)
433.43MEUR526.21M · vs all stocks (USD)
Revenue per Share (TTM)
14.06EURUpdated Sep 23, 2026Quarterly Revenue Growth
41.60%Gross Profit (TTM)
99.10MEUR120.31M · vs all stocks (USD)
EBITDA (TTM)
28.34MEUR34.41M · vs all stocks (USD)
Net Income (TTM)
13.65MEUR16.57M · vs all stocks (USD)
Operating Cash Flow (TTM)
50.13MEUR60.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-87.47MEUR-106.20M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
391.87MEURFY2025 · Dec 31, 2025Cost of Goods Sold
325.34MEURFY2025 · Dec 31, 2025Gross Profit
66.53MEURFY2025 · Dec 31, 2025Operating Income
8.69MEUR9.91M · vs all stocks (USD)
Pre-tax Income
-20.06MEURFY2025 · Dec 31, 2025Income Tax Expense
1.11MEURFY2025 · Dec 31, 2025Net Income
-21.17MEURFY2025 · Dec 31, 2025EBIT
-9.73MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
28.34MEURFY2025 · Dec 31, 2025Research & Development
2.28MEURFY2025 · Dec 31, 2025Selling, General & Administrative
27.91MEURFY2025 · Dec 31, 2025Non-operating Interest Income
1.82MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
10.33MEURFY2025 · Dec 31, 2025EPS (Basic)
-0.6400EURFY2025 · Dec 31, 2025EPS (Diluted)
-0.6400EURFY2025 · Dec 31, 2025Basic Shares Outstanding
32.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
32.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-21.17MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
30.57MEURFY2025 · Dec 31, 2025Free Cash Flow
-76.60MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
74.59MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-21.17MEURFY2025 · Dec 31, 2025Stock-based Compensation
2.02MEURFY2025 · Dec 31, 2025Other Non-cash Items
16.47MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
19.11MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
14.13MEURFY2025 · Dec 31, 2025Capital Expenditures
-107.17MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.15MEURFY2025 · Dec 31, 2025Purchase of Investments
-3.39MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-110.56MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
50.00MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-10.00MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-10.00MEURFY2025 · Dec 31, 2025Common Stock Repurchase
-484.00KEURFY2025 · Dec 31, 2025Other Financing Charges
-773.00KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
28.74MEURFY2025 · Dec 31, 2025Shares Outstanding
33.02MSharesUpdated Sep 23, 2026Float Shares
12.97MSharesUpdated Sep 23, 2026% Held by Insiders
60.52%vs all stocks
% Held by Institutions
13.93%vs all stocks
Total Cash (MRQ)
55.76MEUR67.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.79EURUpdated Sep 23, 2026Total Debt (MRQ)
140.94MEUR171.11M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4248xCurrent Ratio (MRQ)
1.64xBook Value per Share (MRQ)
10.07EURUpdated Sep 23, 2026Total Assets
825.96MEUR941.71M · vs all stocks (USD)
Total Current Assets
324.88MEURFY2025 · Dec 31, 2025Total Liabilities
485.36MEURFY2025 · Dec 31, 2025Total Non-current Assets
501.08MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
298.83MEURFY2025 · Dec 31, 2025Total Current Liabilities
186.53MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
74.59MEURFY2025 · Dec 31, 2025Accounts Receivable
60.86MEURFY2025 · Dec 31, 2025Inventory
154.25MEURFY2025 · Dec 31, 2025Accounts Payable
74.31MEURFY2025 · Dec 31, 2025Short-term Debt
5.55MEURFY2025 · Dec 31, 2025Other Current Liabilities
1.34MEURFY2025 · Dec 31, 2025Long-term Debt
125.01MEURFY2025 · Dec 31, 2025Common Stock (Book)
302.00KEURFY2025 · Dec 31, 2025Retained Earnings
122.63MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
340.60MEUR388.33M · vs all stocks (USD)
Treasury Stock
6.47MEURFY2025 · Dec 31, 202552-Week Low
21.80CHFUpdated Sep 23, 202652-Week High
50.10CHFUpdated Sep 23, 202652-Week Change
81.69%vs all stocks
Beta
1.00xvs all stocks
50-Day MA
44.09CHFUpdated Sep 23, 2026200-Day MA
34.90CHFUpdated Sep 23, 2026Avg 10-Day Volume
87.08KSharesUpdated Sep 23, 2026Avg 30-Day Volume
130.68KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
0.4200EURUpdated Sep 23, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.78: safe zoneNotable
Altman Z-Score: 2.78
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.77B, above the global median of $1.18BNotable
Market cap (USD): 1,767,714,643.682Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule